Information Provided By: 
Fly News Breaks for January 10, 2019
BMRN
Jan 10, 2019 | 08:52 EDT
After meeting with management, Jefferies analyst Eun Yang keeps a Buy rating on BioMarin with a $125 price target. With multiple clinical/regulatory catalysts in 2019, BioMarin is well positioned for upside, Yang tells investors in a research note. She believes the third-year durability data for valox in mid-2019 could potentially move the shares 20%.
News For BMRN From the Last 2 Days
